Full text is available at the source.
Abstract
The safety profile of GLP-1 receptor agonists is incompletely characterized.
- GLP-1 receptor agonists are commonly used to treat type 2 diabetes and obesity.
- Potential safety concerns include psychiatric, vascular, neoplastic, and rare eye-related events.
- The current understanding of these safety issues may be affected by various biases, such as confounding by indication and notoriety bias.
Simplified